AzTrials
AzTrials

Bipolar Disorder (BD)Phase 2PEDALNCT07239778

The PEDAL Intervention - Reducing Affective Lability in Bipolar Disorder

A Phase 2 study testing Traditional group psychoeducation for bipolar disorder and Group psychoeducation with digital elements and focus on affective lability in people with Bipolar Disorder (BD), run by Oslo University Hospital at 4 sites in Norway.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

PEDAL is a group-based intervention for patients with bipolar disorder that builds on the traditional group psychoeducational program (GPP) by adding digital tools and specific strategies to help manage rapid fluctuations between affective states, known as affective lability. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Bipolar Disorder (BD)
What is being tested?
Traditional group psychoeducation for bipolar disorder and Group psychoeducation with digital elements and focus on affective lability
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
4 sitesNorway
Study dates
1 Dec 2025to Jun 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Bipolar I, II or not otherwise specified disorder
  • Understands Scandinavian language
  • Owns and will use smartphone as part of the intervention
  • Is considered eligible for group participation by treating clinician

Who cannot join

  • Previous participation in group psychoeducation for bipolar disorder
  • Will move, is late in pregnancy or other situation that prevents competion of trial

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Trine V. Lagerberg, Professor contact

+47 22 92 35 01

t.v.lagerberg@psykologi.uio.no

Margrethe C. Høegh, PhD contact

+47 23 02 73 30

machoe@ous-hf.no

Norway4 sites, 4 recruiting
  • Vestre Viken Hospital Trust (Drammen DPS)

    Drammen, 3018

    Irene Norheim, Occupational therapist, +47 32 86 18 00, Irene.Norheim@vestreviken.no

    Lena W. Molteberg, Head of Section, + 47 32 86 18 00, LenaWicklund.Molteberg@vestreviken.no

    Recruiting
  • Oslo University Hospital (Nydalen DPS and Søndre Oslo DPS)

    Oslo, 0351

    Erlend Eikenæs, Cand.psychol, +47 23 02 33 00, erleik@ous-hf.no

    Hanne Vørrang, Psychiatric nurse, +47 23 02 30 00, hanvor@ous-hf.no

    Recruiting
  • Diakonhjemmet Hospital (Allmennpsykiatrisk poliklinikk)

    Oslo, 0373

    Marcus Gabrielsen, Cand.med., +47 22 02 98 00, marcus.gabrielsen@diakonsyk.no

    Recruiting
  • Lovisenberg Diaconal Hospital (Section for Group Treatment)

    Oslo, 0440

    Helle Jannecke Elvebredd, Psychotherapist/section head, +47 23 22 50 00, hellejanecke.elvebredd@lds.no

    Jan Vegard Bakali, PhD, + 47 23 22 50 00, jan-vegard.bakali@lds.no

    Recruiting

Other trials in Norway

About this study

Official title: The PEDAL Intervention - Reducing Affective Lability in Bipolar Disorder - a Randomised Controlled Trial

PEDAL is a group-based intervention for patients with bipolar disorder that builds on the traditional group psychoeducational program (GPP) by adding digital tools and specific strategies to help manage rapid fluctuations between affective states, known as affective lability. The program's goal is to help patients learn and develop new ways to better manage their condition, with particular attention to affective lability and other difficulties with affect regulation- challenges which are not typically addressed in current treatments.

The PEDAL trial will run at five clinical sites around Oslo and Vestre Viken, aiming to recruit 120 participants with bipolar disorder. The program combines existing group sessions from GPP with new components: additional group sessions focusing on strategies for improving affect regulation such as mindfulness and distress tolerance, an online platform with all course materials including instructional videos and other resources, and an app-based mood diary. This framework maintains the benefits of regular group meetings while adding digital support tools to make the intervention more personalized and accessible.

Read more

The main aim of PEDAL is to see if the new program reduces affective lability more effectively than GPP (treatment-as-usual; TAU), and both intervention groups will be compared on the level of affective lability before and after the intervention. Several secondary outcomes like mood symptoms, suicidal thoughts, perceived stress, and quality of life will also be assessed. In terms of study design, all study sites will run the PEDAL and TAU groups in parallel, and participants will be randomly assigned to either PEDAL or TAU.

To qualify for the study, participants must be aged 18-65, diagnosed with bipolar disorder, able to participate in a group intervention, capable of providing informed consent, and have a smartphone or computer. People who have previously completed group psychoeducation, who are unable to complete the study period due to pregnancy or other factors, or those who cannot use the required technology are excluded.

In summary, PEDAL is a novel study that modernizes the existing group psychoeducational program for bipolar disorder by targeting affective lability through skills training and digital tools, while also evaluating its reception and effects in a controlled clinical trial.

Read the detailed description

Bipolar disorder (BD) is a severe mental illness with significant costs for the affected individuals, their families, and society. Although a substantial proportion of individuals with BD respond relatively well to currently available treatment, sub-syndromal affective symptoms and affective lability (AL) are common and have a clear negative impact on functioning and quality of life. Targeting AL is an important new opportunity for intervention with high clinical potential through its links to severe outcomes, both independently and as a mediator of other risk factors. There is also a need for interventions that can easily be implemented in regular clinical practice. As such, we have a clear ambition of achieving efficacy and cost-efficiency, i.e., that the PEDAL intervention can be implemented in standard clinical settings without requiring substantial additional resources or structural changes. If successful, we believe that the PEDAL trial will contribute to increasing the quality and availability of treatment for patients with BD. Since group psychoeducation (GPP) is already implemented across many health regions in Norway and worldwide, there is potential for the PEDAL intervention to have both nationwide and international reach and impact if the current trial is successful.

PEDAL (PsychoEducation with Digital elements and focus on Affective Lability) is a group intervention for individuals with BD with educational and therapeutic elements. Its main purpose is to facilitate a learning and developmental process for the patient, in order to enable better self-management of the disorder. PEDAL builds on the well-established GPP program for BD, which has been found to be effective in reducing relapses and hospitalisations. GPP is likely to have further untapped potential in targeting additional burdensome aspects of BD and augmenting the didactic elements. In PEDAL, we reinforce traditional GPP through digital tools and several components targeting affective lability. In a randomised controlled trial, we will investigate whether the PEDAL intervention is superior to traditional GPP in reducing affective lability in BD. Five catchment-area-based clinical sites in and close to Oslo will participate, covering a total population of approximately 740.000. We aim to recruit 120 patients with BD to the trial.

AL is defined as rapid, excessive, and unpredictable shifts in affective states, is common in individuals with BD and adds to the illness burden. It is, however, not targeted successfully in current pharmacological or non-pharmacological treatments. Although a substantial proportion of individuals with BD respond relatively well to currently available treatment, sub-syndromal affective symptoms and AL have a clear negative impact on functioning and quality of life. Targeting AL is an important new opportunity for intervention with high clinical potential through its links to severe outcomes, both independently and as a mediator between e.g. early traumatic experiences and clinical expressions of BD.

New digital tools are promising for enhancing treatments and empowering individuals with mental disorders including BD. Such tools are increasingly used to expand mental health services' availability, flexibility, and personalization. These tools often require limited resources and enable the provision of quality health care irrespective of geographical location. Digital interventions currently in use in the mental health field include online and app-based cognitive behavioural therapy interventions, training of coping skills, and self-help programs with or without therapist guidance. The functional possibilities of digital tools align well with the objectives of psychoeducation, and such tools are increasingly used to enhance its availability and improve the personalization of delivery. So far, studies of digital interventions have not shown the anticipated effects in reducing affective episodes or hospitalisations in BD, or the effects, if present, have not been maintained at follow-up. One possible explanation could be that these interventions do not encompass interactive group sessions. Although they are still based on the principles of psychoeducation, they have omitted the group format, which is highly significant. Consequently, combining the well-established group format with digital tools directed at self-monitoring and self-management, such as an app-based mood diary and skills training sessions, may be a novel and more effective way of increasing empowerment, awareness, and engagement with the intervention.

Traditional GPP consists of modules, where predefined topics are addressed in group sessions and in paper-based written material for the participants to read and prepare for the relevant session. The most frequently used version of GPP in Norway comprises 10-12 weekly group sessions that are relatively independent of each other. The sessions cover topics such as the characteristics of BD, theories about etiology, managing depression and mania, psychopharmacological treatment and lifestyle advice to enhance illness stabilization. Each session has an introductory lecture on the topic held by the therapist, small-group discussions based on the participants' experiences in this area, and plenary discussions led by the therapist. The written material is provided in a booklet. It contains the educational parts, a toolkit with a mood diary, an overview of potential "warning signs" for relapse and an emergency plan. The toolkit is used to engage the participants in self-management of their disorder. Traditional GPP is generic in that it addresses the "standard bipolar patient", i.e. provides limited optional material targeting the specific needs of the individual participants. Furthermore, while the existing program improves several clinical outcomes in BD, it does not specifically target AL and does not appear to affect suicidality - the most severe clinical outcome possibly mediated by AL. Consequently, there is a need to incorporate additional elements to reduce suicide risk. Targeting AL through, e.g., improving affect regulation skills has the potential to do so.

The content of the PEDAL intervention:

The intervention will include the original sessions of GPP while enhancing the program with the following elements:

  1. A new group session specifically addressing AL: Characteristics, and theories about etiology, as well as an introduction to relevant coping skills such as mindfulness, affect regulation strategies and distress tolerance.
  2. A practical skills training group session, where mindfulness, affect regulation and distress tolerance strategies are demonstrated by a therapist.
  3. An online platform with the following content:
  • All written course material for participants, including self-management tools (overview of coping strategies, emergency plan, etc.).
  • Three video tutorials for further skills training; mindfulness, affect regulation, and distress tolerance techniques.
  • All written course material, including an intervention manual for the PEDAL therapists.
  • A brief online "Clinician's booklet" for other clinicians involved in treating the patients attending the intervention.
  1. App-based mood diary ("MyPEDAL").

Aims and hypotheses: The short-term and main aim of the current study is to test whether the PEDAL intervention is more efficient in reducing AL compared to traditional GPP, which is considered TAU in the current trial. We hypothesize that enhancing the traditional GPP for BD with new elements, as planned in the PEDAL intervention, will reduce AL in individuals with BD. It is also an aim to ensure that the PEDAL intervention is well received by patients and clinicians.

The PEDAL trial is a randomised controlled trial, where patients with BD will receive either TAU or the PEDAL intervention. To test whether the PEDAL intervention is more efficient than TAU in reducing AL, we will compare the two groups on pre- and post-intervention assessments of AL (primary outcome). We will also test for group differences on other relevant outcomes with important implications for individuals affected by BD such as affective symptoms, suicidal ideation, perceived stress, and quality of life. To investigate to which degree the PEDAL intervention is well received by patients and clinicians, we will conduct structured post-study evaluations of both arms.

All the clinical units participating in the PEDAL trial normally run traditional GPP 2-3 times a year with 12-16 patients in each group. Patients are referred to GPP from other units within the secondary psychiatric services and, in some cases, from general practitioners or contract psychiatrists and psychologists. All five study sites will run one TAU arm and one PEDAL arm in parallel, and patients will be randomized to TAU or PEDAL. Thus, approximately 60 participants will receive TAU, and 60 will receive PEDAL in the trial.

Inclusion and exclusion criteria: Routine criteria for participation in GPP in adult psychiatric units are as follows and will form the basis for which patients are considered candidates for the PEDAL trial: age between 18 and 65 years, a BD diagnosis, a clinical state that is considered adequate for group participation (i.e. the patient is not in a severe depressive or manic state or has severe ongoing substance abuse) and has adequate understanding of Scandinavian language. In addition, the following inclusion criteria will apply for the current trial: Ability to give informed consent and a valid DSM-5 or ICD-10 diagnosis of bipolar I, II or NOS disorder. Exclusion criteria are: Previous participation in GPP, pregnancy in a stage preventing completion of the intervention, and not owning a smartphone or computer, and/or objecting to the use a mood diary app.

Being tested
Traditional group psychoeducation for bipolar disorder, Group psychoeducation with digital elements and focus on affective lability
Keywords
Affective lability, Bipolar disorder, Psychoeducation, Group intervention, Emotion regulation, Digital tools, eHealth
Medical subject headings
Bipolar Disorder, Emotional Regulation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Traditional group psychoeducation for bipolar disorderBehavioural

    Psychosocial intervention

  • Group psychoeducation with digital elements and focus on affective labilityBehavioural

    Also called The PEDAL intervention

    Psychosocial intervention

Study groups in NCT07239778
Study groupRoleWhat they receive
TAU: Traditional group psychoeducation for bipolar disorderActive comparatorTraditional GPP for bipolar disorder consists of 11 group sessions led by one or two trained therapists. The sessions comprise predefined topics such as the characteristics of BD, theories about etiology, managing depression and mania, psychopharmacological treatment, and lifestyle advice to enhance illness stabilization. Each session has an introductory lecture on the topic held by the therapist, small-group discussions based on the participants' experiences in this area, and plenary discussions led by the therapist. The program also provides written material for the participants to read and prepare for the relevant session, provided in a booklet. It contains the educational parts, a toolkit with a mood diary, an overview of potential "warning signs" for relapse, and an emergency plan. The toolkit is used to engage the participants in self-management of the disorder.
Receives: Behavioral: Traditional group psychoeducation for bipolar disorder
PEDAL: Group psychoeducation with digital elements and focus on affective labilityExperimentalThe PEDAL arm provides the 11 group sessions as described for the comparator arm, and two additional sessions that have been developed for the trial to cover topics related to affective lability and emotion regulation. Thus, in this arm there will be 13 group sessions. The format of the sessions is the same as for the TAU arm. In addition, participants in this arm will have access to an online platform with the following content: All written course material, three video tutorials for emotion regulation skills training, and an app-based mood diary that provides a dashboard where participants can monitor their mood and sleep patterns.
Receives: Behavioral: Group psychoeducation with digital elements and focus on affective lability

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline to follow-up 1 (week 13 in TAU and week 15 in PEDAL) on the 18 item Affective Lability Scale - short form (ALS-SF)

    The Affective Lability Scale is a validated self-report instrument assessing the typical pattern and level of affective lability, from 0 (not very descriptive of me) to 3 (very descriptive of me). Change = Follow-up 1 total score minus baseline total score.

    Measured: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)

Secondary outcomes (7)
  1. Perceived Stress Scale (PSS-10)

    The Perceived Stress Scale (PSS) is a validated self-report measure used to assess the degree to which a person perceives their life as stressful, unpredictable, and uncontrollable over the past month. The scale consists of 10 items rated on a 5-point Likert scale from 0 (never) to 4 (very often). Higher scores indicate higher levels of perceived stress. Change=follow-up 1 total score minus baseline total score.

    Measured: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)

  2. Quick Inventory of Depressive Symptoms - self-report version (QIDS-SR)

    The Quick Inventory of Depressive Symptoms - self-report version (QIDS-SR) is a validated self-report measure to screen for and measure the severity of depressive symptoms in the past 7 days. The scale consists of 16 items rated on a 4-point Likert scale ranging from 0 (not present) to 3 (severe), where a higher score indicates more severe depression. Change= follow-up 1 total score minus baseline total score.

    Measured: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)

  3. The Bech-Rafelsen Mania Scale (BRMS)

    The Bech-Rafelsen Mania Scale (BRMS) is an 11-item clinician-rated scale used to measure the severity of manic symptoms in patients with bipolar disorder over the past 3 days. A higher score indicates more severe symptoms, with 11 items scored from 0 (no/low level) to 4 (high level) corresponding to different levels of mania, such as mild, moderate, or severe. Change= follow-up 1 total score minus baseline total score.

    Measured: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)

  4. Difficulties in Emotion Regulation Scale - Short Form (DERS-SF)

    Difficulties in Emotion Regulation Scale - Short Form (DERS-SF) is a validated 18-item self-report questionnaire used to measure difficulties in a person's capasity to regulate their emotions. The scale consists of 18 items rated on a 5-point Likert scale from 1 (almost never) to 5 (almost always), where higher scores indicate greater difficulties with emotion regulation. Change=follow-up 1 total score minus baseline total score.

    Measured: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)

  5. WHO-5 Well-Being Index

    The WHO-5 Wellbeing Index is a short, self-report questionnaire with 5 items that measures mental well-being over the past two weeks rated on a 6-point Likert scale from 5 (all of the time) to 0 (at no time).The scores are transformed into a percentage score from 0 to 100, where a higher score indicates better well-being. Change=follow-up 1 total score minus baseline total score.

    Measured: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)

  6. EQ-5D-5L

    The EQ-5D-5L is a standardized self-report questionnaire used to measure health-related quality of life across five dimensions, each with five levels of severity. It is a widely used tool for clinical and economic evaluations, and it allows for the assessment of a patient's health status irrespective of their disease and a single index value for health status. Change=follow-up 1 index value minus baseline index value.

    Measured: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)

  7. Suicidal ideation/behavior

    Simple, structured self-report form developed by the study group.

    Measured: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Nov 2025
  2. Study start1 Dec 2025
  3. Primary completion30 Dec 2026 (estimated)
  4. Study completionJun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07239778
Sponsor's protocol ID
875821
Other IDs
340534
Acronym
PEDAL
Status last verified
Sep 2026
First submitted
16 Nov 2025
Last updated
4 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data is considered too difficult to anonymise.

Publications

  • Rozental A, Kottorp A, Boettcher J, Andersson G, Carlbring P. Negative Effects of Psychological Treatments: An Exploratory Factor Analysis of the Negative Effects Questionnaire for Monitoring and Reporting Adverse and Unwanted Events. PLoS One. 2016 Jun 22;11(6):e0157503. doi: 10.1371/journal.pone.0157503. eCollection 2016.

    PubMed 27331907
  • Faurholt-Jepsen M, Frokjaer VG, Nasser A, Jorgensen NR, Kessing LV, Vinberg M. Associations between the cortisol awakening response and patient-evaluated stress and mood instability in patients with bipolar disorder: an exploratory study. Int J Bipolar Disord. 2021 Mar 1;9(1):8. doi: 10.1186/s40345-020-00214-0.

    PubMed 33644824
  • Topp CW, Ostergaard SD, Sondergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-76. doi: 10.1159/000376585. Epub 2015 Mar 28.

    PubMed 25831962
  • Visted E, Solbakken OA, Maeland S, Fadnes LT, Bjerrum LB, Nordhus IH, Flo-Groeneboom E. Validation of a brief version of the Difficulties in Emotion Regulation Scale (DERS-16) with an older Norwegian population. Eur J Ageing. 2023 Jun 22;20(1):26. doi: 10.1007/s10433-023-00775-w.

    PubMed 37347324
  • Miola A, Cattarinussi G, Antiga G, Caiolo S, Solmi M, Sambataro F. Difficulties in emotion regulation in bipolar disorder: A systematic review and meta-analysis. J Affect Disord. 2022 Apr 1;302:352-360. doi: 10.1016/j.jad.2022.01.102. Epub 2022 Jan 29.

    PubMed 35093412
  • Dork J, Mangan E, Burns L, Dimenstein E. Affective Instability: Impact of Fluctuating Emotions on Regulation and Psychological Well-Being. Behav Sci (Basel). 2024 Sep 6;14(9):783. doi: 10.3390/bs14090783.

    PubMed 39335997
  • Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 1;54(5):573-83. doi: 10.1016/s0006-3223(02)01866-8.

    PubMed 12946886
  • Lagerberg TV, Aminoff SR, Aas M, Bjella T, Henry C, Leboyer M, Pedersen G, Bellivier F, Icick R, Andreassen OA, Etain B, Melle I. Alcohol use disorders are associated with increased affective lability in bipolar disorder. J Affect Disord. 2017 Jan 15;208:316-324. doi: 10.1016/j.jad.2016.09.062. Epub 2016 Oct 14.

    PubMed 27810713
  • Licht RW, Jensen J. Validation of the Bech-Rafaelsen Mania Scale using latent structure analysis. Acta Psychiatr Scand. 1997 Nov;96(5):367-72. doi: 10.1111/j.1600-0447.1997.tb09931.x.

    PubMed 9395155
  • Aas M, Pedersen G, Henry C, Bjella T, Bellivier F, Leboyer M, Kahn JP, Cohen RF, Gard S, Aminoff SR, Lagerberg TV, Andreassen OA, Melle I, Etain B. Psychometric properties of the Affective Lability Scale (54 and 18-item version) in patients with bipolar disorder, first-degree relatives, and healthy controls. J Affect Disord. 2015 Feb 1;172:375-80. doi: 10.1016/j.jad.2014.10.028. Epub 2014 Oct 23.

    PubMed 25451440
  • Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016 Apr 9;387(10027):1561-1572. doi: 10.1016/S0140-6736(15)00241-X. Epub 2015 Sep 18.

    PubMed 26388529
  • Joas E, Backman K, Karanti A, Sparding T, Colom F, Palsson E, Landen M. Psychoeducation for bipolar disorder and risk of recurrence and hospitalization - a within-individual analysis using registry data. Psychol Med. 2020 Apr;50(6):1043-1049. doi: 10.1017/S0033291719001053. Epub 2019 May 6.

    PubMed 31057138
  • Hidalgo-Mazzei D, Reinares M, Mateu A, Nikolova VL, Bonnin CDM, Samalin L, Garcia-Estela A, Perez-Sola V, Young AH, Strejilevich S, Vieta E, Colom F. OpenSIMPLe: A real-world implementation feasibility study of a smartphone-based psychoeducation programme for bipolar disorder. J Affect Disord. 2018 Dec 1;241:436-445. doi: 10.1016/j.jad.2018.08.048. Epub 2018 Aug 14.

    PubMed 30145515
  • Depp CA, Ceglowski J, Wang VC, Yaghouti F, Mausbach BT, Thompson WK, Granholm EL. Augmenting psychoeducation with a mobile intervention for bipolar disorder: a randomized controlled trial. J Affect Disord. 2015 Mar 15;174:23-30. doi: 10.1016/j.jad.2014.10.053. Epub 2014 Nov 8.

    PubMed 25479050
  • Faurholt-Jepsen M, Lindbjerg Tonning M, Fros M, Martiny K, Tuxen N, Rosenberg N, Busk J, Winther O, Thaysen-Petersen D, Aamund KA, Tolderlund L, Bardram JE, Kessing LV. Reducing the rate of psychiatric re-admissions in bipolar disorder using smartphones-The RADMIS trial. Acta Psychiatr Scand. 2021 May;143(5):453-465. doi: 10.1111/acps.13274. Epub 2021 Jan 26.

    PubMed 33354769

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Traditional group psychoeducation for bipolar disorder and Group psychoeducation with digital elements and focus on affective lability in people with Bipolar Disorder (BD), run by Oslo University Hospital at 4 sites in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Trine V. Lagerberg, Professor (+47 22 92 35 01, t.v.lagerberg@psykologi.uio.no), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline to follow-up 1 (week 13 in TAU and week 15 in PEDAL) on the 18 item Affective Lability Scale - short form (ALS-SF) (time frame: Baseline, week 13/15 (follow-up 1) and week 37/39 (follow-up 2)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07239778, which also lists 25 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
PEDAL Clinical Trial NCT07239778 | AzTrials